Advent Life Sciences | Activity | F4

Team Portfolio Raise Essays

F4/Advent Life Sciences/Activity

Advent Life Sciences Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Investment

Co-led Sitala Bio's Series B financing in 2025.

Sitala Bio

Sitala Bio Advent Life Sciences

Added recently

Milestone

Portfolio company Beacon Therapeutics reported positive topline data from the pivotal VISTA trial of laru-zova in XLRP.

Beacon Therapeutics

Beacon Therapeutics Advent Life Sciences

adventls.comSEP 22, 2026

SEP 22, 2026

Team Change

Appointed Gail Jermyn as Investor Relations Partner to lead investor relations and fundraising.

Gail Jermyn joined as Investor Relations Partner

Advent Life Sciences

adventls.comSEP 3, 2026

SEP 3, 2026

Milestone

Portfolio company Pheno Therapeutics received FDA IND clearance for PTD802 in multiple sclerosis.

Pheno Therapeutics

Pheno Therapeutics Advent Life Sciences

adventls.comJUN 22, 2026

JUN 22, 2026

Investment

Participated in Cyted Health's $44M Series B led by EQT Life Sciences.

Cyted Health

Cyted Health Advent Life Sciences

adventls.comSEP 2025

SEP 2025

New Fund

Closed two funds totalling $215M, including the Advent-Harrington Impact Fund.

Two new funds totalling $215M

Advent Life Sciences

adventls.comFEB 18, 2021

FEB 18, 2021